Anti-Müllerian hormone: structure, properties and appliance

Rzeszowska, Marzena; Leszcz, Agnieszka; Putowski, Lechosław; Hałabiś, Magdalena; Tkaczuk-Włach, Joanna; Kotarski, Jan; Polak, Grzegorz

doi:10.5603/gp.2016.0064

Cited by 21 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among four enriched pathways, the cytokine-cytokine receptor interaction (mmu04060) and Chemokine signaling pathway (mmu04062) take our attention, which shared 2 genes: CCR7, CXCR2. AMH regulates these receptors, upon which, after a series of putative conformational changes and phosphorylation steps, gene expression is regulated in the cell [ 22 , 23 ]. Chemokines are small peptides that act through limited number of receptors and play an important role to maintain the normal physiology of different organs [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Transcriptome profiling of anti-müllerian hormone treated preantral/small antral mouse ovary follicles

et al. 2018

View full text Add to dashboard Cite

The predisposition for the initiation of folliculogenesis in mammals including humans is programmed to start at fetal life and continues until reproductive capacity. The follicles grow from a pool of primordial follicles which retain the major functions in the entire reproductive life of a female. Anti-müllerian hormone (AMH), a glycoprotein belonging to the transforming growth factor-beta family, has an inhibitory effect on ovarian follicle development. The key regulatory target genes in primordial follicle development are of paramount importance in reproductive biology of female. A systems biology method was used to find regulatory genes performing critical role in primordial follicle development. A complete in-depth bioinformatics analysis was performed to investigate the changes in transcriptome of preantral to small antral mouse follicles treated for 12 h and 24 h with two different concentrations; 50 and 200 ng/ml of AMH, and thereby identify candidate genes in time and concentration manner. Firstly, we found differentially expressed genes that were time and concentration dependent in response to AMH. The network analysis of these differentially expressed genes provided new candidate genes and pathways associated with inhibitory action of AMH on the primordial follicle development. To further emphasize the function of AMH, the key identified genes’ protein-protein docking was analyzed and found the intracellular and extracellular protein-protein interaction. This study elucidates one of the novel mechanisms of AMH involvement in inhibition of ovarian follicle development which may lead to prolong productive life in female.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptome profiling of anti-müllerian hormone treated preantral/small antral mouse ovary follicles

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting substance (MIS), is a dimeric glycoprotein hormone with a molecular weight of 140 kDa. [ 2 ] AMH is well-known for its role as a useful marker of ovarian reserve, as it reflects the size of the resting primordial follicle pool. [ 3 ] In PCOS, AMH is thought to be a potential surrogate marker for the diagnosis particularly in the absence of ultrasound.…”

Section: Introductionmentioning

confidence: 99%

Serum Anti-Müllerian hormone in polycystic ovary syndrome and its relationship with insulin resistance, lipid profile and adiponectin

Jun

Jelani

Omar

et al. 2020

Indian J Endocr Metab

View full text Add to dashboard Cite

Objectives: This study was done to estimate serum anti-Müllerian hormone (AMH) level in polycystic ovary syndrome (PCOS) patients and to correlate serum AMH level with insulin resistance, lipid profile, and adiponectin levels. Materials and Methods: A cross-sectional study was conducted at Hospital Universiti Sains Malaysia (Hospital USM), Health Campus, Kubang Kerian, Kelantan, Malaysia. Thirty newly diagnosed patients with PCOS attending gynecology clinic between July 2016 and April 2017 were recruited. Fasting venous blood samples were collected from the subjects. Serum AMH, insulin, adiponectin, triglycerides, high-density lipoprotein cholesterol (HDL-C), and plasma glucose levels were measured, and insulin resistance was calculated based on homeostasis model of assessment-insulin resistance (HOMA-IR). The serum AMH level was estimated, and the correlation of serum AMH level with the metabolic parameters was analyzed. Results: The median of serum AMH levels in women with PCOS was 6.8 ng/mL (interquartile range: 7.38 ng/mL). There was a significant negative correlation between serum AMH and HOMA-IR or triglyceride levels ( r = −0.49, P = 0.006 and r = −0.55, P = 0.002, respectively). A significant positive correlation was observed between serum AMH and serum HDL-C or serum adiponectin levels ( r = 0.56, P = 0.001 and r = 0.44, P = 0.014, respectively) in all study subjects. Conclusion: The serum AMH level is associated with HOMA-IR, triglycerides, HDL-C, and adiponectin levels, and hence it may be used as a potential cardiometabolic risk marker in women with PCOS.

show abstract

“…Smad6 which acts as a negative regulation of both BMP and TGF-beta/activin-signaling inhibits nuclear translocation of the activated complex leading to transcriptional suppression of Smad 1, 5, 8 targets. An accessory pathway through AMH stimulated b-catenin activation and subsequent binding to LEF-1 (Lymphoid Enhancer Binding Factor 1) further induces expression of Smad-dependent genes [ 3 , 6 , 7 ]. (Pink cell) FSH binding to the Fshr G protein-coupled receptor has been shown to activate the Gαs/cAMP/protein kinase A (PKA) signaling pathway [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…Transcriptomic data were relayed upon the known FSH and AMH interactomes to underpin the effects of each hormonal driver upon this interaction. The AMH interactome was found to be significantly enriched in our differentially expressed genes with hits such as SMAD family members 1, 4, and 5 ( SMAD1 , SMAD4 , SMAD5 ), ALK1 (Activin A receptor like type 1), and LEF1 (Lymphoid Enhancer Binding Factor 1), which are significant members of the AMH signaling cascade [ 4 , 6 , 7 ]. We further pursued this biological link in retrospective, clinical data of 80 patients, to investigate whether AMH presented a more sensitive indicator of IVF outcomes such as oocytes retrieved per cycle, oocytes fertilized (day 2, grades A and B embryos), and number of day 3 embryos.…”

Section: Introductionmentioning

confidence: 99%

Combinational approach of retrospective clinical evidence and transcriptomics highlight AMH superiority to FSH, as successful ICSI outcome predictor

Kastora

Triantafyllidou

Kolovos

et al. 2020

J Assist Reprod Genet

View full text Add to dashboard Cite

Objective Combination of transcriptomic and retrospective clinical data, to assess anti-Mullerian hormone (AMH) functionality at a cumulus cell level and evaluate AMH potential as a suitable marker for IVF outcomes (oocytes retrieved, number of day 3 embryos, gestation outcomes). Design Raw RNA-sequencing data of cumulus cells sourced from younger ( n = 10) patient group (group A) (age 29 (1 year of age), baseline FSH 7.4 (0.5 mIU/ml), AMH 4.67 (1.56 ng/ml)) and older ( n = 10) patient group (group B) (age 43 (± 0.55 years of age), baseline FSH 8 (0.8 mIU/ml), AMH 1.07 (0.44 ng/ml)) were employed to derive transcriptomic differences among high vs. low AMH groups. We collected retrospectively patient data from 80 infertile patients selected according to pre-specified inclusion criteria. Setting Publicly available raw RNA-sequencing data were retrieved from the SRA database of NCBI resource GEO Accession (GSM21575/35-44; GEO Accession: GSM21575/45-55). Retrospective data were collected from referrals to the Institute of Reproductive Medicine, Lito Hospital of Athens and the Institute of Life, Iaso Hospital of Athens, between the periods of March 2015 and April 2018. Intervention(s) A fixed human menopausal gonadotropin (hMG) antagonist protocol was used for all patients. All patients had serum AMH levels measured within a 3-month period prior to stimulation and serum levels of FSH and estradiol (day 2 of menstrual cycle; E2) (Clinical Trial code NV24042014). Main outcome measure(s) The primary outcomes were identification of transcriptomic variations among high (group A) vs. low (group B) AMH patients. Retrospective data primary outcomes were number of oocytes retrieved, fertilized successfully (grades A and B, day 2 embryos), and total number of day 3 embryos. Secondary outcome was live birth rate. Finally, we compared primary outcomes with AMH and FSH level as well as their genetic pathways (interacting genes) to demonstrate the predictive accuracy. Results Essential players of the AMH signaling cascade, namely, SMAD1 , SMAD4 , SMAD5 , ALK1 , and L EF1 , were significantly upregulated in group A ( n 10) transcriptome. This biological clue was further supported by retrospective clinical data ( n 80 participants), where AMH was positively correlated with both oocytes retrieved and fertilized as well as number of day 3 (grades A and B) embryos from patients undergoing IVF, in a statistically significant manner. AMH was further positive trend of association with successful pregnancy outcomes. Conclusion Overall, this study offers new insight on AMH effects upon cumulus cells and new aspects on...

show abstract

Anti-Müllerian hormone: structure, properties and appliance

Cited by 21 publications

References 26 publications

Transcriptome profiling of anti-müllerian hormone treated preantral/small antral mouse ovary follicles

Transcriptome profiling of anti-müllerian hormone treated preantral/small antral mouse ovary follicles

Serum Anti-Müllerian hormone in polycystic ovary syndrome and its relationship with insulin resistance, lipid profile and adiponectin

Combinational approach of retrospective clinical evidence and transcriptomics highlight AMH superiority to FSH, as successful ICSI outcome predictor

Contact Info

Product

Resources

About